Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Net Margin: 2009-2025

Historic Net Margin for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 11.81%.

  • Gyre Therapeutics' Net Margin rose 740.00% to 11.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.20%, marking a year-over-year increase of 9077.00%. This contributed to the annual value of 11.43% for FY2024, which is 9334.00% up from last year.
  • Gyre Therapeutics' Net Margin amounted to 11.81% in Q3 2025, which was up 615.38% from 1.65% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Net Margin high stood at 27.72% for Q1 2024, and its period low was -1,830.73% during Q1 2022.
  • Moreover, its 3-year median value for Net Margin was 9.00% (2023), whereas its average is -24.81%.
  • As far as peak fluctuations go, Gyre Therapeutics' Net Margin plummeted by 150,475bps in 2021, and later spiked by 183,973bps in 2023.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Net Margin stood at -832.34% in 2021, then soared by 80,287bps to -29.47% in 2022, then tumbled by 34,259bps to -372.06% in 2023, then soared by 37,170bps to -0.36% in 2024, then skyrocketed by 740bps to 11.81% in 2025.
  • Its last three reported values are 11.81% in Q3 2025, 1.65% for Q2 2025, and 12.23% during Q1 2025.